

Agenda item 5.i

Report to:	Board of Directors	Date: 3 October 2019
Report from:	Dr Ian Smith Deputy Medical Director	
Principal Objective/Strategy:	Information	
Title:	Research and Development Update	
Board Assurance Framework Entries:	730	
Regulatory Requirement:		
Equality Considerations:	Non believed to apply	
Key Risks:	Failure to give R&D strategic recognition	
For:	Information	

1. Purpose

To provide an overview of Research and Development activities for the Board.

2. Research Strategy

The Trust has a draft research strategy, but this is on-hold whilst the Trust Strategy and Cambridge-wide research strategy are finalised to ensure that the Research Strategy is congruous with these. Dr Ron Zimmern is leading the development of the Cambridge-wide cardiothoracic research strategy and the next phase of this work is due to start at the beginning of 2020.

3. HLRI

Work is underway in the lead up to the opening of the HLRI. A number of joint committees have been initiated with the University of Cambridge with representation from Royal Papworth Hospital and the University of Cambridge including Digital, Scientific Committee and Clinical Research Facility.

The biggest challenge for the Research & Development Directorate is that due to the reduced Trust footprint within the HLRI, the Research Tissue Bank will no longer be housed here. Space will need to be identified on the Biomedical Campus for the laboratory and office space for Tissue bank and Research pathology staff. A working group has been set-up by the Trust led by Wendy Walker.

4. Recruitment to portfolio studies

We have recruited 625 patients to CRN portfolio studies since April 2019. This is the highest rate in since 2016/17. This is even more impressive when you consider that this is over the hospital move period.

5. Clinical Trials Unit

The clinical trials unit is currently working with 2 investigators (Prof A Klein and Dr M Toshner) following provisional approval of their applications worth over £3m in total.

6. Recommendation

The Board of Directors is requested to note the R&D update.